| Amount | Holding |
|---|---|
| 18.59% | Johnson & Johnson |
| 14.78% | Merck & Co Inc |
| 4.07% | Eli Lilly and Co |
| 3.82% | Zoetis Inc Class A |
| 3.71% | Elanco Animal Health Inc |
| 3.56% | Mylan NV |
| 3.55% | Bristol-Myers Squibb Company |
| 3.52% | Allergan PLC |
| 3.43% | Pfizer Inc |
| 2.88% | Catalent Inc |
Expense Ratio Rating
1 /10
Expense Rating
0 /10
Market Score
2 /10
Category Score
0 /10
Market Size
2 /10
ProFunds Pharmaceuticals UltraSector Fund Investor Class
Expenses: 1.86% (Better than 0% of similar funds)
This is a bad choice for a Leveraged Equities Alternative fund. See why ยป
| Amount | Holding |
|---|---|
| 18.59% | Johnson & Johnson |
| 14.78% | Merck & Co Inc |
| 4.07% | Eli Lilly and Co |
| 3.82% | Zoetis Inc Class A |
| 3.71% | Elanco Animal Health Inc |
| 3.56% | Mylan NV |
| 3.55% | Bristol-Myers Squibb Company |
| 3.52% | Allergan PLC |
| 3.43% | Pfizer Inc |
| 2.88% | Catalent Inc |
Minafi - The intersection of FI, minimalism & mindfulness.
Don't miss out on new posts, courses, interactive articles and more!
Join & Get Your First Course Free© 2025 Adam Fortuna
Site Map